Private Placement and Share Price Reaction: Evidence from the Australian Biotechnology and Health Care Sector
This paper analyses Private Placements for the Australian biotechnology sector. Private placement is one of the favoured methods of secondary equity offering around the world. However, it is also the least studied corporate financing mechanism. A major issue around private placement is the impact of issuance to a selected group of institutional and/or high net worth sophisticated investors and the high direct costs of doing so. We first employ en event study methodology to separate out the large and small placement effects and short and long run effects. Given Australia’s weaker regulatory environment, we find significant negative cumulative abnormal return following private placements in the short term supporting the price pressure hypothesis with our main sample and with large private placement issues. Consistent with current empirical studies, mixed evidence regarding the directional impact was also observed as small issue exhibited positive price effects. We then hypothesize a model to measure and test the key factors identified in the literature. The model captures and explains strong medium term cumulative abnormal return effects and these effects are quite different between small and large placements.
|Date of creation:||21 Apr 2007|
|Date of revision:|
|Contact details of provider:|| Postal: 221 Burwood Highway, Burwood 3125|
Phone: 61 3 9244 3815
Fax: +61 3 5227 2655
Web page: http://www.deakin.edu.au/buslaw/aef/index.php
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:dkn:acctwp:aef_2007_05. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dr Xueli Tang)
If references are entirely missing, you can add them using this form.